Quarterly ResultMay 18, 2026, 07:02 AM
Compugen Q1 2026 Net Loss $7.7M; Cash Runway into 2029
AI Summary
Compugen reported a net loss of $7.7 million, or $0.08 per share, on revenues of $2.2 million for the first quarter of 2026. This compares to a net loss of $7.2 million and revenues of $2.3 million in the prior year period. The company highlighted continued progress across its clinical programs, including active enrollment in the COM701 MAIA-ovarian trial and AstraZeneca's advancement of rilvegostomig in 11 Phase 3 trials. Compugen maintains a solid financial position with a cash runway expected to fund operations into 2029.
Key Highlights
- Cash, cash equivalents, and marketable securities totaled $134.9 million as of March 31, 2026.
- Compugen expects its cash runway to fund operating plans into 2029.
- Revenue for Q1 2026 was $2.2 million, compared to $2.3 million in Q1 2025.
- Net loss for Q1 2026 was $7.7 million, or $0.08 per basic and diluted share.
- R&D expenses increased to $6.9 million in Q1 2026 from $5.8 million in Q1 2025.
- COM701 MAIA-ovarian trial is actively enrolling patients, with interim analysis on track by Q1 2027.
- Partner AstraZeneca is advancing rilvegostomig across 11 ongoing Phase 3 trials.
- Partnerships with AstraZeneca and Gilead offer approximately $1 billion in potential milestones plus royalties.
Price Impact
More from CGEN